TINEA
MCID: DRM011
MIFTS: 46

Dermatophytosis (TINEA) malady

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Dermatophytosis

Aliases & Descriptions for Dermatophytosis:

Name: Dermatophytosis 12 14 69
Tinea 69

Classifications:



External Ids:

Disease Ontology 12 DOID:8913
ICD10 33 B35 B35.9
ICD9CM 35 110 110.9
NCIt 47 C26745
UMLS 69 C0011636

Summaries for Dermatophytosis

Disease Ontology : 12 A cutaneous mycosis that results_in fungal infection located in scalp, located in glabrous skin, or located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which have the ability to utilize keratin as a nutrient source.

MalaCards based summary : Dermatophytosis, also known as tinea, is related to deep dermatophytosis and tinea corporis, and has symptoms including exanthema, fever and pruritus. An important gene associated with Dermatophytosis is CARD9 (Caspase Recruitment Domain Family Member 9), and among its related pathways/superpathways are Defensins and Cytokines and Inflammatory Response. The drugs Ketoconazole and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells.

Wikipedia : 71 Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a... more...

Related Diseases for Dermatophytosis

Diseases related to Dermatophytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 102)
id Related Disease Score Top Affiliating Genes
1 deep dermatophytosis 12.2
2 tinea corporis 11.8
3 tinea cruris 11.7
4 tinea pedis 11.7
5 tinea capitis 11.7
6 tinea manuum 11.5
7 tinea unguium 11.5
8 tinea barbae 11.3
9 tinea profunda 10.9
10 candidiasis, familial, 2, autosomal recessive 10.7
11 superficial mycosis 10.7
12 dermatomycosis 10.7
13 tinea imbricata 10.2
14 esophagitis 10.2 DEFB4A SQLE
15 dicrocoeliasis 10.2 DEFB4A SQLE
16 kleefstra syndrome 10.1 CARD9 CLEC7A
17 pontiac fever 10.1 CARD9 CLEC7A
18 asymptomatic dengue 10.1 CARD9 CLEC7A
19 posterior mediastinum cancer 10.1 KATNAL2 SLC7A1
20 ectropion 10.1 CARD9 CLEC7A
21 handl syndrome 10.1 CLEC7A LTF
22 gonadal disease 10.0 CLEC7A DEFB4A
23 chronic gonorrhea of cervix 10.0 CARD9 CLEC7A DEFB4A
24 lambda 5 deficiency 10.0 CARD9 CD4
25 bullous retinoschisis 10.0 CD4 DEFB4A
26 hypoparathyroidism-retardation-dysmorphism syndrome 9.9 CD4 LTF
27 dieulafoy lesion 9.9 CARD9 CD4
28 sclerosing cholangitis 9.9 CD4 DEFB4A LTF
29 perinatal necrotizing enterocolitis 9.9 CD4 LTF
30 gonococcal synovitis 9.9 CD4 CLEC7A
31 total internal ophthalmoplegia 9.9 CD4 CLEC7A
32 candidiasis 9.9
33 congenital hypothyroidism 9.8 CARD9 CD4 CLEC7A
34 chronic mucocutaneous candidiasis 9.8
35 motor peripheral neuropathy 9.8 CARD9 CD4 CLEC7A
36 rheumatoid factor-negative juvenile idiopathic arthritis without anti-nuclear antibodies 9.8 CD4 LTF
37 bladder diverticulum 9.8 CD4 CLEC7A
38 urticaria 9.8
39 dermatitis 9.8
40 psoriasis 9.8
41 pemphigus 9.8
42 tinea favosa 9.7
43 kerion celsi 9.7
44 keratitis 9.7
45 erythema multiforme 9.7
46 lymphoma 9.7
47 sarcoma 9.7
48 ichthyosis 9.7
49 acquired immunodeficiency syndrome 9.7
50 rheumatoid arthritis 9.5

Comorbidity relations with Dermatophytosis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Dermatophytosis:



Diseases related to Dermatophytosis

Symptoms & Phenotypes for Dermatophytosis

UMLS symptoms related to Dermatophytosis:


exanthema, fever, pruritus

Drugs & Therapeutics for Dermatophytosis

Drugs for Dermatophytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65277-42-1 47576 3823
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Bifonazole Approved Phase 4,Phase 3,Phase 2 60628-96-8 2378
5
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 91161-71-6 5402 1549008
6
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2 29342-05-0 2749
7
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2 84625-61-6 55283
8
Naftifine Approved Phase 4,Phase 3,Phase 2,Phase 1 65472-88-0 73342 47641
9
Efinaconazole Approved Phase 4,Phase 3 164650-44-6
10
Proton pump inhibitors Phase 4
11 Gastrointestinal Agents Phase 4,Phase 3
12 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
13 Amorolfine Phase 4,Phase 3,Phase 2,Phase 1
14 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
15 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
16 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Dermatologic Agents Phase 4,Phase 2
18 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
19 Hormones Phase 4,Phase 3,Phase 2,Phase 1
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
21 Antacids Phase 4
22 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Keratolytic Agents Phase 4
26 Anti-Ulcer Agents Phase 4
27 Hydroxyitraconazole Phase 4,Phase 3,Phase 2
28
Clotrimazole Approved, Vet_approved Phase 3,Phase 1 23593-75-1 2812
29
Econazole Approved Phase 3,Phase 2 27220-47-9 3198
30
Tolnaftate Approved, Vet_approved Phase 3 2398-96-1 5510
31
Sertaconazole Approved Phase 3 99592-32-2 65863
32
Fluconazole Approved Phase 3 86386-73-4 3365
33
Griseofulvin Approved, Vet_approved Phase 3 126-07-8 441140
34
Albendazole Approved, Vet_approved Phase 2, Phase 3 54965-21-8 2082
35
Tavaborole Approved Phase 3,Phase 2,Phase 1 174671-46-6
36
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
37
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
38 Trace Elements Phase 2, Phase 3
39 Peripheral Nervous System Agents Phase 3,Phase 2
40 Anthelmintics Phase 2, Phase 3
41 Anti-Asthmatic Agents Phase 3,Phase 2
42 Anti-Inflammatory Agents Phase 3,Phase 2
43 Respiratory System Agents Phase 3,Phase 2
44 Antimitotic Agents Phase 2, Phase 3
45 Micronutrients Phase 2, Phase 3
46 Autonomic Agents Phase 3,Phase 2
47 Antiparasitic Agents Phase 2, Phase 3
48 Antiprotozoal Agents Phase 2, Phase 3
49 Betamethasone Valerate Phase 3 2152-44-5
50 Dexamethasone acetate Phase 3 1177-87-3

Interventional clinical trials:

(show top 50) (show all 182)
id Name Status NCT ID Phase
1 Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Unknown status NCT02394340 Phase 4
2 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
3 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4
4 An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis Completed NCT02466867 Phase 4
5 Pediatric Subjects With Tinea Corporis Completed NCT02227290 Phase 4
6 Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4
7 Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Completed NCT01712360 Phase 4
8 Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Completed NCT02767947 Phase 4
9 Ketoconazole Foam 2% for the Treatment of Versicolor Completed NCT00830388 Phase 4
10 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4
11 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4
12 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4
13 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4
14 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4
15 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4
16 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4
17 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Recruiting NCT02812771 Phase 4
18 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4
19 Study Evaluating the Effect of Jublia on Dermatophytomas Active, not recruiting NCT03098615 Phase 4
20 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Active, not recruiting NCT03110029 Phase 4
21 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4
22 Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Unknown status NCT00856596 Phase 3
23 Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Unknown status NCT01105013 Phase 3
24 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3
25 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
26 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3
27 Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3
28 Topical Antifungal Treatment for Tinea Cruris Completed NCT01342315 Phase 3
29 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3
30 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3
31 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396811 Phase 3
32 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396785 Phase 3
33 Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis Completed NCT01433107 Phase 3
34 Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Completed NCT01349998 Phase 3
35 Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis Completed NCT00802672 Phase 3
36 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris Completed NCT00750152 Phase 3
37 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis Completed NCT00750139 Phase 3
38 Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3
39 Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Completed NCT03129321 Phase 3
40 Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Completed NCT01353976 Phase 3
41 Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Completed NCT01358240 Phase 3
42 A Study Of Diflucan In Children With Ringworm Of The Scalp Completed NCT00645242 Phase 3
43 BE Study of Naftifine HCL Completed NCT02633813 Phase 3
44 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3
45 Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride Versus 5% Amorolfine Nail Lacquer in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3
46 Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443898 Phase 3
47 Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail Completed NCT00443820 Phase 3
48 Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01302119 Phase 3
49 Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01270971 Phase 3
50 Safety and Efficacy of Luliconazole Solution, 10% in Subjects With Mild to Moderate Onychomycosis Completed NCT01431820 Phase 2, Phase 3

Search NIH Clinical Center for Dermatophytosis

Genetic Tests for Dermatophytosis

Anatomical Context for Dermatophytosis

MalaCards organs/tissues related to Dermatophytosis:

39
Skin, Testes, T Cells, Thymus, Monocytes, Liver, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatophytosis:

18
Nail, Scalp, Glabrous Skin

Publications for Dermatophytosis

Articles related to Dermatophytosis:

(show top 50) (show all 586)
id Title Authors Year
1
Isotretinoin may affect pharmacokinetics of itraconazole in the skin: Is it rational to combine both for the treatment of dermatophytosis? ( 27853005 )
2017
2
Correlation between histopathologic features and likelihood of identifying superficial dermatophytosis with periodic acid Schiff-diastase staining: a cohort study. ( 27859475 )
2017
3
Trichophyton rubrum tinea capitis in an HIV-positive patient with generalized dermatophytosis. ( 28050591 )
2017
4
Dermatophytosis among Schoolchildren in Three Eco-climatic Zones of Mali. ( 27124571 )
2016
5
Progredient dermatophytosis and nevus anemicus: aA pathogenetic mediated relationship. ( 27577247 )
2016
6
Comparison of two systemic antifungal agents, itraconazole and terbinafine, for the treatment of dermatophytosis in European hedgehogs (Erinaceus europaeus). ( 27620985 )
2016
7
Natural Products: An Alternative to Conventional Therapy for Dermatophytosis? ( 27771883 )
2016
8
The Use of Adhesive Tapes to Transfer Skin-scrapings for Sequential Laboratory Diagnosis of Dermatophytosis. ( 26936345 )
2016
9
Diagnosis of Dermatophytosis Using Molecular Biology. ( 27480761 )
2016
10
Dermatophyte abscesses caused by Trichophyton rubrum in a patient without pre-existing superficial dermatophytosis: a case report. ( 27317023 )
2016
11
Male genital dermatophytosis - clinical features and the effects of the misuse of topical steroids and steroid combinations - an alarming problem in India. ( 27028087 )
2016
12
Fluorescence Microscopy as a Diagnostic Tool for Dermatophytosis. ( 26894772 )
2016
13
Relapse after Oral Terbinafine Therapy in Dermatophytosis: A Clinical and Mycological Study. ( 27688443 )
2016
14
The Role of Phagocytes and NETs in Dermatophytosis. ( 27659806 )
2016
15
'Ring-within-a-ring' appearance: morphological clue to topical steroid abuse in dermatophytosis. ( 26856975 )
2016
16
Epidemiological trends of dermatophytosis in Tehran, Iran: A five-year retrospective study. ( 27520535 )
2016
17
Efficacy of Topical Therapy with Newly Developed Terbinafine and Econazole Formulations in the Treatment of Dermatophytosis in Cats. ( 27760032 )
2016
18
Dermatophytosis in donkeys (Equus asinus) due to Microsporum racemosum, an unusual geophilic agent. ( 27453813 )
2016
19
Medication Practice of Patients with Dermatophytosis. ( 27935915 )
2016
20
Efficacy and tolerability of topical sertaconazole versus topical terbinafine in localized dermatophytosis: A randomized, observer-blind, parallel group study. ( 28066103 )
2016
21
Clinical application of a molecular assay for the detection of dermatophytosis and a novel non-invasive sampling technique. ( 27780596 )
2016
22
Evaluation of the Efficacy of ME1111 in the Topical Treatment of Dermatophytosis in a Guinea Pig Model. ( 26833160 )
2016
23
Dermatophytosis: fluorostaining enhances speed and sensitivity in direct microscopy of skin, nail and hair specimens from dermatology outpatients. ( 26931645 )
2016
24
Congenital Ichthyosiform Erythroderma Superimposed with Chronic Dermatophytosis: A Report of Three Siblings. ( 26645853 )
2016
25
Dermatophytosis in northern Africa. ( 26692117 )
2016
26
Epidemiological Aspects of Dermatophytosis in Khuzestan, southwestern Iran, an Update. ( 26886443 )
2016
27
The menace of chronic and recurrent dermatophytosis in India: Is the problem deeper than we perceive? ( 27057485 )
2016
28
Successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole. ( 27297276 )
2016
29
Equine Dermatophytosis: A Survey of Its Occurrence and Species Distribution among Horses in Kaduna State, Nigeria. ( 27340592 )
2016
30
Pathogenesis of Dermatophytosis: Sensing the Host Tissue. ( 27590362 )
2016
31
Trichophyton rubrum Infection Characterized by Majocchi's Granuloma and Deeper Dermatophytosis: Case Report and Review of Published Literature. ( 28004227 )
2016
32
Modeling dermatophytosis in reconstructed human epidermis: A new tool to study infection mechanisms and to test antifungal agents. ( 27760830 )
2016
33
Dermoscopic features in canine dermatophytosis: some preliminary observations. ( 27917539 )
2016
34
Efficacy of pomades containing different percentages of enilconazole in the treatment of bovine dermatophytosis. ( 26990840 )
2016
35
Comparison between point-of-care dermatophyte test medium and mycology laboratory culture for diagnosis of dermatophytosis in dogs and cats. ( 27237544 )
2016
36
Dectin-1 and Dectin-2 promote control of the fungal pathogen Trichophyton rubrum independently of IL-17 and adaptive immunity in experimental deep dermatophytosis. ( 27189427 )
2016
37
Can Routine Histopathology Distinguish Between Vulvar Cutaneous Candidosis and Dermatophytosis? ( 27093036 )
2016
38
Clinico-microbiological study of dermatophytosis in a tertiary-care hospital in North Karnataka. ( 27559499 )
2016
39
Are Th17 Cells Playing a Role in Immunity to Dermatophytosis? ( 27878642 )
2016
40
Evaluation of dermoscopy in the diagnosis of naturally occurring dermatophytosis in cats. ( 27311364 )
2016
41
Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis. ( 26720159 )
2016
42
Dermatophytosis in patients with human immunodeficiency virus infection: Clinical aspects and etiologic agents. ( 26200786 )
2015
43
Applicability of an Anti-Trichophyton Monoclonal Antibody for the Immunohistochemical Diagnosis of Human Fungal Skin Infections (Dermatophytosis) in Tissue Sections. ( 25590286 )
2015
44
Assessment of Dermatophytosis Treatment Studies: Interpreting the Data. ( 26461835 )
2015
45
Zoonotic importance of canine scabies and dermatophytosis in relation to knowledge level of dog owners. ( 27065644 )
2015
46
Relationship among Short and Long Term of Hypoinsulinemia-Hyperglycemia, Dermatophytosis, and Immunobiology of Mononuclear Phagocytes. ( 26538824 )
2015
47
A homozygous CARD9 mutation in a Brazilian patient with deep dermatophytosis. ( 26044242 )
2015
48
Diagnosis of dermatophytosis: an evaluation of direct examination using MycetColorAr and MycetFluoAr. ( 26227326 )
2015
49
Incidence and etiological agents of genital dermatophytosis in males. ( 25669337 )
2015
50
Equine Dermatophytosis due to Trichophyton bullosum, a Poorly Known Zoophilic Dermatophyte Masquerading as T. verrucosum. ( 26290003 )
2015

Variations for Dermatophytosis

Expression for Dermatophytosis

Search GEO for disease gene expression data for Dermatophytosis.

Pathways for Dermatophytosis

Pathways related to Dermatophytosis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.5 CD4 DEFB4A LTF
2 10.1 CD4 CSF1

GO Terms for Dermatophytosis

Biological processes related to Dermatophytosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase activity GO:0045860 9.43 CD4 CSF1
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.43 CARD9 CD4 LTF
3 antimicrobial humoral response GO:0019730 9.4 DEFB4A LTF
4 T cell activation GO:0042110 9.37 CD4 CLEC7A
5 killing of cells of other organism GO:0031640 9.32 DEFB4A LTF
6 positive regulation of monocyte differentiation GO:0045657 9.16 CD4 CSF1
7 defense response to Gram-negative bacterium GO:0050829 9.13 CD4 DEFB4A LTF
8 immune system process GO:0002376 9.02 CARD9 CD4 CLEC7A CSF1 LTF

Sources for Dermatophytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....